2 PDE4 Inhibitors – A Review of the Current Field
Authors:
- Katharine H. BannerKBKatharine H. Banner
- 1 January 2009
- book chapter
- Published by Elsevier
- Vol. 47, 37-74
Abstract
No abstract availableThis publication has 164 references indexed in Scilit:
- Short‐term or long‐term treatments with a phosphodiesterase‐4 (PDE4) inhibitor result in opposing agonist‐induced Ca2+ responses in endothelial cellsBritish Journal of Pharmacology, 2008
- Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitorsBiochemical Journal, 2007
- Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illnessThe Journal of Physiology, 2007
- Profiling human phosphodiesterase genes and splice isoformsBiochemical and Biophysical Research Communications, 2006
- An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary diseaseBritish Journal of Clinical Pharmacology, 2006
- Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitorsLife Sciences, 2004
- Type 4A cAMP-specific phosphodiesterase is stored in granules of human neutrophils and eosinophilsCell and tissue research, 2003
- Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4British Journal of Pharmacology, 1998
- Characterization of the Isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021Cellular Signalling, 1996
- Shift toward T lymphocytes with a T helper 1 cytokine‐secretion profile in the joints of patients with rheumatoid arthritisArthritis & Rheumatism, 1996